Is Now the Right Time to Buy Moderna Stock?
Thanks to its globally in-demand coronavirus vaccine, Moderna (NASDAQ: MRNA) is one of the hottest companies on the market right now. And with the pandemic continuing worldwide despite the slow distribution of effective vaccines, it's safe to say that its product will be lucrative for quite some time.
But does that make Moderna's stock a buy for new investors? Or has the market already priced in the expectation that the company's revenue will continue to soar as its manufacturing capabilities scale up and allow it to access more and more of the global coronavirus vaccination market? In my view, Moderna will probably continue to outperform, but there's a solid chance that its growth could soon either slow down -- or potentially accelerate.
Image source: Getty Images.
Source Fool.com
